IPCA Laboratories

“Our domestic formulation business for Q2 FY '27 has delivered growth of around 14%, and it has reached to around INR1,157 crores as against INR1,019 crores in Q2 FY '26.”

“on chronic segment MAT September 2026, Ipca has achieved a growth of around 20% as against IPM growth of around 17%.”

“On export formulation business, on a stand-alone basis, Ipca has grown by 32% in Q2 FY '27 to around INR653 crores as against INR493 crores in Q2 FY '26.”

“Our promotional branded business in ROW markets has delivered growth of 19% for Q2 FY '27 to around INR172 crores against INR145 crores in Q2 FY '26.”

“Generic market, excluding tender, delivered around 36% growth in Q2 FY '27 to around INR364 crores as against INR268 crores in Q2 FY '26.”

“As per IQVIA, the acute segment, Ipca has achieved a growth of around 11%. We are at par with the overall market growth there in acute segment, largely because some of the portfolio like antimalarials and antibacterials are declining”

“For Q2 FY '27, we continue to see significant price increase on inputs, logistic cost, shipping cost and even fuel and your -- energy cost.”

“In spite of all these factors, overall consolidated EBITDA margins have improved to around 22.97% in Q2 FY '27 as against 21.68% in Q2 FY '26.”

“Stand-alone EBITDA margin of Ipca has improved to 26.6% in Q2 FY '27 as against 25.46% in Q2 FY '26.”

“Let's say, Unichem has delivered almost around 11.3% kind of EBITDA margin in current quarter. I think overall because of freight increase, the freight was significantly increased in this particular quarter.”

“If you look at the other expenditure of Unichem, that has moved from INR142 crores to INR189 crores. So there is an increase of almost around 47% in -- INR47 crores in other expenses, out of which almost INR31.2 crores is only increase in the freight expenses.”

“Our interest cost in the quarter 2 has also come down. It's not gone up because last year, we have paid our entire foreign currency debt, which was outstanding in books because we were carrying the cash in books.”

“So right now, we have only a very small borrowing of around INR155 crores or so on rupee term loan, which probably”

“So -- and practically, we are debt-free company because we are getting almost around INR700 crores cash in books and debt are hardly any.”

“That debt also, we are not prepaying because that debt is contracted at very low rate compared to the current market rate of what we are realizing on deploying money in mutual funds and all.”

“Yes, yes, it will decline. Yes, it would decline, yes.”

“overall, I think in first quarter, significant amount of shipment, which was to go in last financial year because of nonavailability of ships and other things, those businesses got shifted in the first quarter of the current year.”

“But overall, we don't expect this business to grow significantly. It may come down also next year here and there.”

“So last year in Europe, in U.K., we have U.K. portfolio, we have suffered in the overall, I think in the whole of the year, maybe around 2.5 million kind of loss in U.K.”

“MAT September 2026, Ipca's rank remained 16 as per IQVIA. Our market share has improved to around 2.11% from -- as against 2.09% in September '26.”

“Zerodol as the umbrella brand has crossed INR1,500 crores sales as per IQVIA in September 2026. It has become the fourth largest brand in IPM.”

“Our consolidated Q2 FY '27 business has grown by around 14% to around INR2,910 crores as against INR2,557 crores.”